Q1 EPS Estimate for Sage Therapeutics Raised by Analyst

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities researchers at Wedbush increased their Q1 2025 EPS estimates for shares of Sage Therapeutics in a research report issued on Wednesday, November 20th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of ($1.31) per share for the quarter, up from their previous forecast of ($1.38). Wedbush currently has a “Neutral” rating and a $8.00 target price on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.50) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.83) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($0.79) EPS and FY2028 earnings at ($0.29) EPS.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The firm’s revenue was up 337.1% on a year-over-year basis. During the same period in the prior year, the company earned ($2.81) EPS.

Several other brokerages have also recently commented on SAGE. Scotiabank cut their price target on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, October 30th. Robert W. Baird cut their price target on Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a report on Wednesday, October 9th. StockNews.com cut Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Truist Financial reduced their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada raised Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research report on Thursday, November 21st. Three investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $12.83.

Sage Therapeutics Stock Performance

NASDAQ SAGE opened at $5.76 on Monday. The stock’s 50 day moving average price is $6.65 and its two-hundred day moving average price is $8.95. The stock has a market capitalization of $352.36 million, a price-to-earnings ratio of -1.03 and a beta of 0.92. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $28.26.

Institutional Trading of Sage Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Sage Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after buying an additional 3,757 shares during the period. State Street Corp raised its holdings in shares of Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after purchasing an additional 451,377 shares during the period. RTW Investments LP boosted its position in shares of Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after purchasing an additional 111,123 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Sage Therapeutics in the 3rd quarter valued at about $208,000. Finally, Martingale Asset Management L P increased its position in Sage Therapeutics by 55.1% in the 3rd quarter. Martingale Asset Management L P now owns 47,077 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 16,717 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.